Graft-versus-host disease (GVHD) remains a major complication of bone marrow transplantation. This report describes reversal of GVHD by infusion of stored re cipient bone marrow following combined liver-bone marrow allotransplantation. Graft-versus-host disease developed at the end of the first postoperative week. The skin involvement progressively spread to approximately 80% of the body sur face and was not affected by modification of the immuno suppressive treatment. On the 42nd and 43rd postoperative day 1.23 x 10* and 1.6 x 10 8 autologous bone marrow cells per kg of recipient body weight were infused. The skin rush began to dramatically improve and resolved within 2 wk from the autologous marrow infusion. Autologous bone marrow storage previous to allogeneic bone marrow transplantation for tolerance induction could constitute a safety net in case of occurrence of GVHD.
The concept of graft-versus-host disease (GVHD) as the recognition of the host by immunologically com petent cells of the graft was first delineated by Billingham and Brent (1), following spleen cell and bone marrow transplantation. However, it was soon recog nized that the same problem could affect recipients of organs that are rich in lymphoid tissue (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) . In this report, we describe reversal of GVHD by infusion of stored autologous bone marrow in a recipient of a combined liver-bone marrow transplant.
CASE REPORT
A 56-yr-old man underwent upper abdominal exen teration and liver transplantation on July 16, 1992 for a gastric leiomyosarcoma with liver metastases. Using standard techniques autologous bone marrow cells were harvested before the surgical procedure and stored in liquid nitrogen (14) . A few hours before op eration, the patient was treated with a single dose of 550 rads thoraco-abdominal lymphoid irradiation (TLI). Bone marrow cells from the same donor as the liver allograft were separated from vertebral bodies ob tained at the time of the multiorgan donor procedure. Then, 2 X 108 bone marrow cells per kg of recipient body weight were infused IV through a central line im mediately after the orthotopic liver transplant. Post operative immunosuppression was with conventional doses of FK 506 and prednisone ( Fig. 1) .
A skin rash developed at the end of the first post operative week that was initially mild and confined to the areas exposed to the preoperation irradiation. The rash worsened during the second postoperative week, and on the 15th postoperative day (POD), the diagno sis of GVHD that was Grade 2 by the criteria of Lerner et al. (13) was made on a skin biopsy. On days 21 and 32 progressively more florid changes compatible with acute GVHD were seen in second and third skin biop sies. The skin biopsy obtained on POD 15 showed a mild, predominantly r-lymphocyte infiltrate localized to the upper dermis and associated with focal exocytosis and spongiosis. Occasional keratinocyte necrosis was present. Immunoperoxidase studies disclosed that the infiltrating cells were of donor HLA type. The sec ond biopsy on POD 21 revealed more florid changes which included acantholysis and focal cleft formation ACCEPTED (13) . The biopsy on POD 32 showed similar changes with continued damage to keratinocytes and adnexal cells (Fig. 2b) and a significantly more conspicuous inflammatory infil trate of the upper dermis than previously. Immunoperoxidase stains showed the cells to be 7"-lymphocytes of donor origin. Stains for Epstein-Barr virus were neg ative. Grossly, the skin involvement spread to approx imately 80% of the body surface, including the palms, soles, and face. Its progress was not altered by increases or decreases of FK 506 or prednisone. Bouts of eosinophilia (2,040/mm 3 ) and diarrhea were recorded. On the 42nd and 43rd POD posttransplantation, 1.23 X 108 and 1.6 x 108 autologous BMC/kg were infused. Fig. 2c ). Seven days af ter this (POD 54), skin biopsies had less evidence of acute GVHD ranging from Grade 0 to 2 (Fig. 2d ). By this time, the rash caused by GVHD had largely re solved. No additional biopsies were obtained.
The skin rash began to dramatically improve 1 wk af ter the autologous cell infusion and had largely re solved after 2 wk. At skin biopsy, four days after the autologous marrow infusion (POD 47), the donor cell infiltrate was less. Focal exocytosis of mononuclear

cells was found in association with ballooning of ba sal cells and aggregates of necrotic keratinocytes in the upper layers of the epidermis (
The patient, who had been seriously ill, was restored to a sense of well being and was discharged. How ever, on October 13 (90 POD), he was readmitted with jaundice. A needle biopsy of the liver was diag nosed as acute viral hepatitis. Because of the additional diagnosis of partial biliary obstruction from ampullary dysfunction, the biliary reconstruction of choledochodochostomy was converted to a Roux-y-choledochojejunostomy on October 22, 1992. Another liver biopsy was obtained intraoperatively with which the diagno sis of C-virus hepatitis (HCV) was confirmed by iden tification of viral RNA using the polymerase chain reaction (PCR). A recipient lymph node and a segment of bowel excised for the biliary reconstruction were taken for immunocytochemical staining and histopath ologic staining. After immunocytochemical staining, both the intraabdominal lymph node and segment of jejunum contained sparsely distributed donor cells. This degree of chimerism has been associated with graft acceptance and donor specific nonreactivity (15).
For the 1.5 mo before as well as after the biliary re construction, minimum immunosuppression was given with 1 mg FK 506, every other day and 5 mg/day pred nisone. Alpha-interferon therapy was started on Oc tober 27. The patient was discharged on November 20. On February 24,1993, when the bilirubin was 1.2 mg%, immunosuppression with FK 506 was discontinued with continuation of 2.5 mg prednisone. On May 4, 1993, he was admitted with a bilirubin of 1.9 mg% which rose over the next 13 days to 9.7 mgm%. Retransplantation was performed on May 17, 1993, but the patient died 4 mo later after repeated intraabdom inal and systemic infections. Histopathologically, the primary allograft had findings of hepatitis but there also was evidence of rejection with obliterative arteriopathy and diffuse small duct loss.
Flow cytometry (FACS II, Becton Dickinson & Co., Mountain View, CA) was used to determine the relative percentages of PBL bearing HLA Class I specific for the donor or recipient. Blood was collected and RBC
were ACK-Iysed. The remaining cells were stained with anti-HLA Class I monoclonal antibodies (mAbs) (gen erously provided by Dr. Paul Terasaki) for 30 min at 4°C and counterstained with sandwich when required. Donor cells were detected in the peripheral blood from the time of the first analysis, 11 days following liver transplantation. These accounted for 22-34% of the total cell number out to POD 43 (Fig. 1) , but then dra matically decreased following the autologous bone marrow infusion, to 3% at 96 days following trans plantation. On POD 227, cytospin examination of a buffy coat preparation stained with donor MHC reac tive monoclonal antibodies showed < 1 % donor cells. The cytospin during the week before retransplantation was negative for donor cells. ble 1) . For the first month postoperatively, the patient's PBL showed no response to either donor or third party. However, the PBL blood sample from day 32 at the time of florid GVHD was stimulated by the stored autologous pre-transplant PBL (3,946 cpm vs. 269 cpm background). Three days after infusion on POD 42-43 of the autologous marrow, the patient's PBL showed highly significant spontaneous prolifer- (d) Fig. 2(d) . Biopsy on postoperative (POD) 54 from the resolving area of rash shows only a modest mononuclear in filtrate associated with isolated necrotic keratinocytes. Changes of acute GVHD ranged from 0 to 2 in the four sam ples taken at this time (x250).
Donor specific proliferation was assessed in MLR pretransplant and monthly intervals postoperatively for 8 mo. Before surgery, the recipient's lymphocytes exhibited significant proliferative responses to both donor and third party HLA unrelated stimulators (Ta
ation (Table 1) which was not markedly altered by the addition of stored autologous, donor, or recipient cells. However, by POD 62, (20 days after autologous bone marrow infusion) spontaneous proliferation had died down and MLR responses to donor and third party were restored. For the next 2 mo, the patient's proliferative response to donor pretransplant lympho cytes was higher than that to third party. By 7 mo postsurgery, the MLR response to the donor had dropped to only 25% of the response to third party. However, by 10 mo, 6 wk before retransplantation, antidonor party responses had recovered and were similar to those before the primary transplantation.
Significant donor-specific CML activity was ob served with the blood sample on POD 62, 20 days fol lowing autologous bone-marrow infusion (Fig. 3) . Even at a low effector:target ratio (10:1), recipient lym phocytes exhibited 20% donor specific CML activity with no CML reactivity generated towards third party stimulator cells then or later. This donor-specific CML response was not evoked by the donor cells in a sub sequent sample on day 97 at which time a significant proliferative response in MLR still was present.
40-i Donor-Specific Cytotoxic Activity
DISCUSSION
These results indicate that stored autologous bone marrow could constitute a safety net for GVHD in splanchnic organ recipients or in clinical trials of bone marrow transplantation that are designed to induce do nor specific unresponsiveness for whole organ or nonhematolymphopoietic (i.e., islet) cell transplantation. Neither temporary reduction of immunosuppression nor augmentation of treatment affected the GVHD. After the autologous cell infusion, the skin biopsy was better within 4 days, and dramatic clinical improve ment was evident by the end of the week.
Ten days before the bone marrow infusion, the MLR showed no response against donor or third party, indicating the profoundly immunocompromised status of the recipient. This could explain why the recipient peripheral leukocytes were ineffective in control of the GVHD, despite their quantitative advantage relative to the infused bone marrow cells which had been removed and cryopreserved preoperatively, before the patient underwent radiation treatment or was exposed to phar macologic immunosuppression. The infused autologous cells retained their ability to reverse the GVHD, and ultimately, the alloreactivity of the circulating recipient cells to those of the donor was restored to levels that were even higher than those observed pre-transplantation. Eventually, the recipient whose immunosup pression had been stopped regained enough immune competence to reject the graft which also was afflicted with severe HCV. The autologous cell treatment could be considered analogous to the "tolerance breaking" experiments described by Billingham, Brent, and Medawar (16).
